Document is current

Any future updates will be listed below

800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0800

Published Online: 2020-11-09

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark